Local biotech "genius" Mirxes, famous for sniffing out cancer in your blood, has spectacularly failed to sniff out a massive US$14.8 million tumor in its own bank account.

Turns out, predicting the fate of a patient's colon is way easier than explaining to KPMG why you sent $19 million to "vendors" who effectively ghosted the company.

The firm ditched the Singapore Exchange for Hong Kong to find "sophisticated investors," only to get their trading suspended faster than a Yishun siao lang at a police station.

While $9.5 million was miraculously returned, the remaining millions have presumably been spent on premium bird’s nest and expensive "prepayments."

Independent investigation? Please lah. Pattern more than badminton.